CERO CERO THERAPEUTICS HOLDINGS, INC.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1870404 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-259.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,130.6%
Debt / equity—
Current ratio0.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.61x
Accruals ratio157.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.97M | $1.74M | $2.34M | — | $2.39M | $2.75M | $2.91M | $1.77M |
| SG&A expense | $1.22M | $2.11M | $2.51M | — | $1.98M | $1.97M | $2.04M | $2.63M |
| Operating income | -$3.19M | -$3.85M | -$4.85M | — | -$4.36M | -$4.72M | -$4.95M | -$4.40M |
| Interest expense | $917,669 | $690,044 | $166,286 | — | — | — | — | -$4,418 |
| Net income | $4.02M | -$1.03M | -$5.89M | -$4.54M | -$4.86M | -$5.42M | -$5.11M | -$4.23M |
| EBITDA | -$3.14M | -$3.79M | — | — | -$4.29M | -$4.65M | -$4.87M | -$4.29M |
| EPS (basic) | 0.06 | -0.70 | -0.20 | — | -9.10 | -61.71 | -31.82 | -170.22 |
| EPS (diluted) | 0.00 | -0.70 | -0.20 | — | -9.10 | -61.71 | -31.82 | -170.22 |
| Weighted avg. shares (diluted) | 1.09B | 42.18M | 28.76M | — | 1.26M | 488,076 | 171,381 | 24,838 |
| Banking | ||||||||
| Deposits | $196,000 | $609.00B | $509.00B | $1.30M | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $455,925 | $862,756 | $857,489 | $1.66M | $1.95M | $3.23M | $5.10M | $3.38M |
| Current assets | $975,003 | $1.55M | $1.57M | $2.73M | $2.55M | $4.25M | $5.77M | $3.71M |
| PP&E, net | $71,312 | $125,947 | $184,449 | $246,148 | $313,452 | $382,806 | $452,227 | $624,900 |
| Total assets | $1.83M | $1.90M | $2.21M | $3.64M | $3.91M | $6.20M | $7.99M | $6.49M |
| Current liabilities | $20.32M | $32.41M | $11.33M | $9.09M | $8.45M | $7.62M | $7.86M | $9.42M |
| Long-term debt | — | — | $136,765 | — | — | — | — | — |
| Total debt | — | — | $136,765 | — | — | — | — | — |
| Total liabilities | $20.67M | $32.41M | $11.46M | $9.09M | $8.45M | $7.84M | $8.32M | $10.19M |
| Shareholders' equity | -$18.84M | -$30.51M | -$9.26M | -$5.45M | -$4.54M | -$1.63M | -$329,386 | -$3.70M |
| Net debt | — | — | -$720,724 | — | — | — | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.03M | -$7.89M | $2.80M | -$3.83M | -$3.21M | — | — | — |
| Financing cash flow | $2.75M | — | — | — | $1.42M | — | — | — |
| Depreciation & amortization | $54,635 | $58,502 | — | — | $69,354 | $76,294 | $76,294 | $113,855 |
| Stock-based compensation | $121,936 | $1.12M | $1.62M | $259,666 | $348,116 | $183,328 | $304,946 | $400,000 |
| Dividends paid | — | — | $127,144 | $0 | $0 | $0 | $127,144 | — |
Free plan shows the latest 8 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.